SHL is one of the few telehealth companies to achieve tens of millions of euros of sales. Yet the Israeli company, listed on the Swiss stock exchange saw sales fall 19% to $42m with EBITDA down from $11.4m to $9.1m in 2011.  We talk to co-CEO Erez Alroy about why growth is so difficult, how SHL saves German insurers €5,000 a year per patient and how it sells individual subscriptions to Israelis....